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MEETING REPORT
Perspectives in melanoma: Meeting report 
from the Melanoma Bridge (30 November–2 
December, 2017, Naples, Italy)
Paolo A. Ascierto1*†, Igor Puzanov2†, Sanjiv S. Agarwala3, Carlo Bifulco4, Gerardo Botti5, Corrado Caracò6, 
Gennaro Ciliberto7, Michael A. Davies8, Reinhard Dummer9, Soldano Ferrone10, Thomas F. Gajewski11, 
Claus Garbe12, Jason J. Luke13, Francesco M. Marincola14, Giuseppe Masucci15, Janice M. Mehnert16, 
Nicola Mozzillo17, Giuseppe Palmieri18, Michael A. Postow19,20, Stephen P. Schoenberger21, Ena Wang22 
and Magdalena Thurin23*
Abstract 
Metastatic melanoma represents a challenging clinical situation and, until relatively recently, there was an absence of 
effective treatment options. However, in 2011, the advanced melanoma treatment landscape was revolutionised with 
the approval of the anti-cytotoxic T-lymphocyte-associated protein-4 checkpoint inhibitor ipilimumab and the selec-
tive BRAF kinase inhibitor vemurafenib, both of which significantly improved overall survival. Since then, availability 
of new immunotherapies, especially the anti-programmed death-1 checkpoint inhibitors, as well as other targeted 
therapies, have further improved outcomes for patients with advanced melanoma. Seven years on from the first 
approval of these novel therapies, evidence for the use of various immune-based and targeted approaches is con-
tinuing to increase at a rapid rate. Improved understanding of the tumour microenvironment and tumour immuno-
evasion strategies has resulted in different approaches to target and harness the immune response. These new 
immune-based approaches offer the opportunity for various approaches with distinct modes of action being used 
in combination with one another, as well as combined with other treatment modalities such as targeted therapy, 
electrochemotherapy and surgery. The increasing number of treatment options that are now available has resulted 
in a growing need to identify which patients will derive most benefit from which treatments. Much research is now 
focused on the identification of biomarkers that can be utilised to help select patients for treatment. These and other 
recent advances in the management of melanoma were the focus of discussions at the third Melanoma Bridge meet-
ing (30 November–2 December, 2017, Naples, Italy), which is summarised in this report.
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Introduction
Although surgical resection plays a fundamental role 
as a curative approach in the initial stages of malignant 
melanoma when the disease is diagnosed early enough, 
many patients present with more advanced, unresect-
able disease. Metastatic melanoma represents a challeng-
ing problem and, until recently, there were no effective 
treatment options. A review of randomised trials in 
metastatic melanoma that were published up until 2006, 
reported a complete response rate of just 4.1% and a 
median overall survival (OS) of 7  months [1]. However, 
in 2011, the treatment landscape in advanced melanoma 
was revolutionised with the approval of the anti-cyto-
toxic T-lymphocyte-associated protein (CTLA)-4 check-
point inhibitor ipilimumab and the BRAF-targeted 
monoclonal antibody vemurafenib. Both immunother-
apy and targeted therapy significantly improved OS in 
phase III clinical trials [2, 3]. Since then, the approval of 
new immunotherapies, especially the anti-programmed 
death (PD)-1 checkpoint pathway inhibitors, PD1 and 
PD1-ligand (PD-L1), as well as targeted therapies, have 
further improved outcomes for patients with advanced 
melanoma.
Since the approval of the first of these novel thera-
pies, evidence for the use of various immune-based and 
targeted approaches continues to increase. Improved 
understanding of the tumour microenvironment and 
tumour immuno-evasion strategies has resulted in 
different approaches to target and improve the anti-
tumour immune response. These new immune-based 
approaches offer the opportunity for various drugs with 
distinct modes of action to be used in combination with 
one another, as well as with other treatment modalities 
such as targeted therapy, electrochemotherapy and sur-
gery. The increasing number of treatment options that 
are now available has resulted in a growing need to iden-
tify patients who will derive most benefit from specific 
treatments. Much research is now focused on the iden-
tification of biomarkers that can be utilised to help select 
patients for treatment.
A unifying model for cancer immune 
responsiveness
The clinical success of immune checkpoint blockade with 
anti-CTLA-4 and anti-PD-1 or PD-L1 inhibitors in mela-
noma has highlighted the clear survival benefit achieved 
with cancer immunotherapy, which distinguishes it from 
chemotherapy and even targeted therapy. However, the 
next challenge for immunotherapy is to extend its utility 
to a broader range of cancers, including those that appear 
to be immune-resistant. One way to achieve this goal is 
to adopt strategies that combine checkpoint inhibition 
with other treatments.
A complex myriad of models to explain immune resist-
ance to checkpoint inhibitors has been suggested. How-
ever, analysis of data from The Cancer Genome Atlas 
(TCGA) has suggested that cancer cells go through a 
conserved evolutionary bottleneck and face a Two-
Option Choice by which they evade immune recogni-
tion by the immune-competent host. This choice involves 
adopting either an oncogenic process devoid of immu-
nogenic stimuli in which tumour growth is depend-
ent upon a stepwise oncogenic mechanism that avoids 
immune recognition (immune-silent tumours) or show-
ing an entropic biology prone to immune recognition 
(immune-active tumours) but with compensatory immu-
nosuppression [4]. These two processes may result in a 
lack of response to checkpoint blockade through entirely 
distinct mechanisms. Immunotherapy agents including 
checkpoint inhibitors are only effective against immune-
active tumours enriched with immune regulatory mecha-
nisms. However, although an immune-active landscape 
is a prerequisite for immune responsiveness, it is not 
sufficient alone to predict immune response. This may 
be because immune regulatory mechanisms are closely 
correlated in expression with tumour inflammation sig-
natures [e.g., interferon (IFN)-γ-induced Immunologic 
Constant of Rejection (ICR) and tumour inflammation 
signature (TIS) [5]], indicating that immune suppression 
goes hand-in-hand with immune activation.
Future efforts to overcome immunotherapy resistance 
need to consider the immune landscape that is being 
targeted. Immune-active tumours may benefit from 
combined immunotherapies that can overcome immu-
noregulatory mechanisms. However, immune-silent 
tumours may need priming to induce immunogenic cell 
death and promote the recruitment of innate and adap-
tive immune cells before they become suitable targets for 
treatment with checkpoint inhibitors.
System biology in melanoma session
The obesity paradox of melanoma
Obesity is associated with increased risk of several can-
cers, as well as worse outcomes. However, in some can-
cers, obesity may only be linked with worse outcomes in 
early-stage disease, whereas obese patients with later-
stage disease have improved outcomes; this is the so-
called “obesity paradox”.
In melanoma, obese patients with early-stage disease 
(largely clinically localised disease) have been reported 
to have worse OS and worse melanoma-specific sur-
vival (MSS) [6]. This correlation remained significant 
after adjustment for age, gender and stage, but not after 
adjusting for C-reactive protein (CRP). However, in a 
meta-analysis of randomised controlled trials of patients 
(n = 599) with stage IV melanoma treated with combined 
Page 3 of 13Ascierto et al. J Transl Med  (2018) 16:207 
dabrafenib (a BRAF inhibitor) and trametinib (a MEK 
mitogen-activated protein kinase inhibitor), obesity was 
associated with improved outcomes [7]. Indeed, there 
was an inverse linear relationship between body mass 
index (BMI) and hazard ratio (HR), such that the higher 
the BMI, the better the survival. Obese patients had simi-
lar disease-stage, ECOG status and serum lactate dehy-
drogenase (LDH) as normal weight patients but did have 
more frequent use of concomitant aspirin, beta-blockers, 
anti-diabetic drugs (including metformin) and statins. 
However, further analyses showed that the impact of 
obesity on outcomes was independent of these medica-
tions. Similarly, obese melanoma patients treated with 
vemurafenib plus cobimetinib (a MEK inhibitor) showed 
improved OS and progression-free survival (PFS) com-
pared to patients with a normal BMI [7]. Obese patients 
have also shown improved OS and PFS when treated with 
immunotherapy, both with PD-1 monotherapy and with 
ipilimumab plus dacarbazine. However, no association 
between obesity and improved survival was observed in 
melanoma patients receiving dacarbazine chemotherapy 
alone in two separate cohorts. In a multivariate analysis, 
BMI was predictive of response to targeted and immuno-
therapy but was not a prognostic factor. With both tar-
geted therapy and immunotherapy, outcomes were 
gender-specific with the survival advantage conferred 
by obesity driven by strong associations in men with no 
significant association between obesity and outcomes in 
women.
A key question is how the information that men with 
stage IV melanoma have better survival outcomes if they 
are obese rather than normal weight can be utilised. 
Firstly, it is important to ensure that BMI data are col-
lected for patients. BMI may also be a relevant parameter 
to consider in clinical trial design and stratification of 
patients. The impact of obesity at stage III disease should 
also be investigated, along with its effect on other thera-
peutic regimens (e.g. combined PD-1/CTLA-4 block-
ade, flat-dosing). Further research into the association 
of obesity with outcomes at a molecular, metabolic and 
immune response level is required.
Integrating tumour and host factors as coordinated 
biomarkers for immunotherapy
Most responders to immunotherapy have a T cell-
inflamed tumour microenvironment phenotype which 
is characterised by increased chemokine production, 
intratumoural  CD8+ T cells, a type I IFN signature and 
the presence of immune escape inhibitory pathways. 
The activity of anti-PD-1 therapy in patients with head 
and neck cancer, gastric cancer, and others is associated 
with a T cell- inflamed tumour microenvironment phe-
notype at baseline. This phenotype also displays PD-L1 
expression, regulatory T cells (Tregs), and indoleamine-
2,3-dioxygenase (IDO), which are all associated with 
increased  CD8+ T cell infiltration and an immune gene 
signature. In contrast, non-T cell-inflamed tumours are 
characterised by low inflammatory signature and absent 
 CD8+ T cells, and immune escape appears to be medi-
ated by T cell exclusion.
Understanding the molecular mechanisms that under-
lie the presence or absence of this spontaneous anti-
tumour T cell response should enable the development of 
therapeutic solutions for patients lacking T-cell infiltra-
tion. Multiple tumour and host-derived factors appear to 
impact on the generation of the T cell-inflamed tumour 
microenvironment phenotype. These include somatic dif-
ferences at the level of tumour cells, such as mutational 
landscape, antigenic repertoire and distinct oncogene 
pathways that are activated in different patients; germline 
genetic differences at the host level, e.g., polymorphisms 
in immune regulatory genes; as well as environmental 
factors, such as the commensal microbiota, immunologi-
cal/pathogen exposure and patient history.
One example of a distinct melanoma-cell-intrinsic 
oncogenic pathway that contributes to a lack of T-cell 
infiltration in melanoma involves activation of the WNT/
β-catenin signalling pathway, which prevents the host 
anti-tumour immune response by a failure to recruit 
Batf3 dendritic cells (DCs) [8]. β-Catenin-expressing 
tumours are resistant to checkpoint blockade therapy. 
Adoptive transfer of tumour-specific T cells also has been 
shown to not control β-catenin-expressing tumours, by a 
mechanism linked to failed trafficking of effector T cells 
[9]. The recruitment of effector  CD8+ T cells is depend-
ent on CXCL9/10 production by Batf3 DCs, which are 
absent from β-catenin-expressing tumours. This indi-
cates that the absence of  CD103+ DCs within the tumour 
microenvironment resists the effector phase of an anti-
tumour T cell response, contributing to immune escape.
Environmental factors may also contribute to differ-
ences in responses between patients. Direct administra-
tion of a Bifidobacterium mix to tumour-bearing mice 
improved tumour-specific immunity and response to 
anti-PD-L1 treatment [10]. Combination treatment of 
Bifidobacterium plus an anti-PD-1 antibody resulted in 
the near complete stopping of tumour outgrowth, with 
the effect mediated by augmented DC function and 
enhanced  CD8+ T cell priming and accumulation in 
the tumour microenvironment. It has also been shown 
that patients with metastatic melanoma who respond to 
anti-PD-1 therapy have distinct microbiota, with Bifi-
dobacterium longum being one species more abundant, 
compared with non-responders. In addition, anti-PD-
L1 therapy is effective in germ-free mice that receive 
human microbiota from anti-PD-1 responder but not 
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from non-responders. These data suggest that improved 
responses to cancer immunotherapy may be possible by 
manipulation of the microbiota.
Given the multiple potential biomarkers across vari-
ous tissues and compartments, an integrated approach 
that employs machine learning algorithms to identify 
combinatorial patterns of biomarkers linked to anti-PD-1 
efficacy could be a more informative than individual bio-
markers. These machine learning approaches are being 
pursued to identify patterns and personalised mecha-
nisms of resistance and should help maximize predic-
tive biomarker efficacy, generate new hypotheses about 
mechanisms of effect, examine gene-environment inter-
actions and help develop new therapies to expand thera-
peutic benefits.
Rational combination immunotherapy based on gene 
expression profiling
Tumours can be profiled at baseline as either T cell 
inflamed or non-inflamed, with the T cell-inflamed 
tumour microenvironment correlating with the efficacy 
of T cell based immunotherapies. When gene expres-
sion analysis based on the T cell-inflamed phenotype was 
applied to The Cancer Genome Atlas a wide variation in 
frequency of T cell-inflamed samples was observed across 
tumour types, with the highest frequency in clear-cell 
kidney cancer and lung adenocarcinoma and the lowest 
in paraganglioma and low-grade glioma. In melanoma, 
no difference in multiple antigen classes was observed 
between T cell-inflamed and non-inflamed tumours [11]. 
There was also no correlation between gene expression 
and mutational burden in any cancer type, indicating that 
lack of spontaneous immune infiltration is unlikely to be 
caused by the lack of antigens.
Most therapeutic immune targets currently in clini-
cal development show strong correlation with PD-L1 
expression. However, the correlation between PD-L1 
expression level and immunotherapy targets is weaker in 
non-inflamed tumours. Immune target genes can be sep-
arated into those that are strongly correlated with PD-L1 
and those that are weakly correlated. For example, there 
is a strong correlation between high PD-L1 and high T 
cell immunoglobulin and mucin-domain containing-3 
(TIM-3); almost all metastatic melanoma samples have 
either high PD-L1/high TIM-3 or low PD-L1/low TIM-3 
expression. Other therapeutically relevant molecules 
in melanoma that PD-L1 is associated with include, but 
are not limited to, lymphocyte-activation gene (LAG)-3, 
IDO-1, forkhead box (FOX)P3, CTLA-4, colony stimu-
lating factor 1 receptor (CSF1R) and glucocorticoid-
induced tumour necrosis factor receptor (GITR). These 
targets tend to cluster in groups associated with vary-
ing levels of PD-L1 expression in melanoma as well as in 
other highly T cell inflamed tumours, such as head and 
neck cancer, lung adenocarcinoma, clear-cell kidney can-
cer and bladder cancer.
Patient-level immune target identification may be 
feasible and may allow personalised immunotherapy. 
The Adaptive Biomarker Trial that Informs Evolution 
of Therapy after Nivolumab (ADVISE, NCT03335540) 
is designed to evaluate the treatment of solid tumours 
with various nivolumab (a fully human PD-1 immune-
checkpoint-inhibitor antibody) based immunotherapy 
combinations, with treatment choice based on a broad 
biomarker assessment (Fig. 1).
Comprehensive tumour profiling of multiple tumours 
to characterize expression of lymphocyte-activation pro-
tein (LAG)-3 showed that it is moderately co-expressed 
with other immune markers and highly expressed on 
major histocompatibility complex (MHC) II high cells 
[12]. Increased tumour MHC II was observed in both 
inflamed and non-inflamed tumours and correlated with 
LAG-3-positive tumour-infiltrating lymphocytes (TILs). 
Preferential localisation of LAG-3-expressing leuko-
cytes to MHC II high tumour regions potentially serves 
as a mechanism for LAG-3 checkpoint pathway activa-
tion. Tumours with high MHC II expression generally 
had lower PD-L1 expression. LAG-3 was upregulated 
during nivolumab monotherapy. The observation that 
nivolumab may induce LAG-3 expression highlights the 
need to define predictive biomarker profiles for the anti-
LAG-3 agent, relatlimab, in PD-1-naïve and previously-
treated patients.
Biomarker session
Biomarkers for checkpoint inhibition in melanoma: current 
knowledge and future directions
An important aspect of checkpoint inhibitor therapy are 
the durable responses that have been observed in patients 
who discontinue treatment. In the CheckMate-069 trial 
of combined nivolumab and ipilimumab, patients dis-
continuing treatment early due to drug toxicity had a 
high and durable response rate and derived an OS benefit 
that was comparable to that observed in the overall study 
population (18-month OS rate of 80% vs. 73%) [13]. This 
‘first-shot’ theory suggests that response at ~ 3 months is 
an excellent marker of longer-term efficacy in checkpoint 
inhibition. Indeed, the outcome of ‘first-shot’ treatment 
may be the most important biomarker for long-term 
durable clinical success.
PD-L1 expression alone is not a valid selection crite-
rion for treatment. In the CheckMate-067 trial, objective 
response rate (ORR) with nivolumab plus ipilimumab 
was increased in patients with PD-L1 tumour expression. 
However, when compared with ipilimumab alone, ORR 
was 15% higher in patients with PD-L1-positive tumours 
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and 13% higher in patients with PD-L1-negative tumours. 
OS is also improved in patients with PD-L1 expression. 
However, PD-1 antibodies are still effective in patients 
without PD-L1 tumour expression. Murine double min-
ute-2 (MDM2) amplification and hyper-progression 
under checkpoint inhibition may also be a biomarker 
of lack of efficacy. MDM2 is overexpressed in diverse 
tumour types and exerts its oncogenic effects primarily 
through inhibition of the p53 tumour suppressor protein.
The association between blood-based biomarkers 
and outcomes in patients receiving immunotherapy 
has also been widely investigated. In 209 patients with 
advanced melanoma treated with ipilimumab, low 
baseline LDH, low absolute monocyte counts, and low 
 Lin−CD14+HLA−DR−/low-myeloid-derived suppres-
sor cell (MDSC) frequencies were significantly asso-
ciated with improved survival, as were high absolute 
eosinophil counts, high relative lymphocyte counts, 
and high  CD4+CD25+FoxP3+-Treg frequencies [14]. 
Using a combined prognostic score consisting of abso-
lute eosinophil and monocyte counts, relative lympho-
cyte counts and LDH, the number of favourable factors 
(4 vs. 3 vs. 2–0) was also associated with OS. Simi-
larly, in patients treated with pembrolizumab (human-
ized monoclonal IgG4-kappa isotype antibody against 
PD-1), high relative eosinophil count and relative lym-
phocyte counts, low LDH, and absence of metastasis 
other than soft-tissue/lung were independent baseline 
characteristics associated with favourable OS; the pres-
ence of four favourable factors in combination identi-
fied a cohort with excellent prognosis [15]. A prognostic 
score based only on relative eosinophil and lymphocyte 
counts also identified patients most likely to have bet-
ter OS. In another analysis, early increases in absolute 
lymphocyte counts (at 2–8 weeks after the first dose of 
ipilimumab) and delayed increases in  CD4+ and  CD8+ 
T cells (at 8–14 weeks) were correlated with improved 
survival [16]. Further investigation of these peripheral 
blood biomarkers is required. Established prognostic 
markers such as tumour stage and LDH are valid in 
checkpoint inhibitor therapy. However, it is uncertain 
whether lymphocyte and eosinophil counts are predic-
tive or just prognostic markers.
Another possible predictive factor is functional T cell 
response. The presence of circulating T cells respond-
ing to peptides from Melan-A or NY-ESO-1 had strong 
independent prognostic impact on survival in patients 
with distant melanoma metastases [17]. Median OS of 
patients with responsive T cells was 21  months com-
pared with 6  months for patients with non-responsive 
T cells. Patients with ≥ 2 targeted antigens also had 
significantly improved OS versus patients with 0–1 
antigens. Barcode-labelled peptide-MHC multim-
ers enable the combination of functional T cell analy-
sis with large-scale epitope recognition profiling and 
allows the detection of low-frequency CD8 T cells spe-
cific for virus- or cancer-restricted antigens [18].
Fig. 1 Adaptive biomarker trial design
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FOLFIRINOX, immune response and clinical course 
of the disease in pancreatic ductal adenocarcinoma
It has been known for many years that malignant trans-
formation of human cells may be associated with changes 
in the expression of HLA class I and HLA class II anti-
gens. Defects in HLA class I antigen expression and/or 
function by tumour cells have a negative impact on their 
interactions with cognate T cells; as a result, they provide 
tumour cells with an escape mechanism from immune 
surveillance. The anti-tumour activity of chemotherapy 
and radiation is mediated, at least in part, by their ability 
to induce or enhance an anti-tumour immune response. 
In patients with pancreatic ductal adenocarcinoma 
(PDAC), the combination chemotherapy regimen FOL-
FIRINOX (oxaliplatin, irinotecan, fluorouracil, and leuco-
vorin) is associated with improved PFS and OS compared 
with gemcitabine [19]. The beneficial effect of FOL-
FIRINOX on the clinical course of PDAC is in part medi-
ated by the induction of changes that facilitate tumour 
cell recognition by the immune system. In patients with 
PDAC treated with neoadjuvant FOLFIRINOX, there is 
a reduced HLA-A defect frequency. In addition, there 
are significant increases in  CD8+ T cells and Granzyme 
 B+ cells and a significant decrease in  FoxP3+ cell tumour 
infiltration density. A significant increase in  CD4+ cell 
tumour infiltration density in patients treated with 
FOLFIRINOX and proton-beam therapy has also been 
observed, suggesting that chemotherapies have the ability 
to enhance tumour antigen-specific T cells.
Towards precision immunotherapy of solid tumours: 
an HLA‑agnostic functional neoantigen discovery platform
Advances in genomic sequencing and bioinformatics 
have led to numerous demonstrations of spontaneous 
and therapy-induced T cell responses against a subset 
of immunogenic tumour-specific somatic mutations 
referred to as neoantigens, raising the possibility that 
patients could be treated with vaccines personalised 
against the mutations expressed by their own tumour.
Although neoantigens are targets for T cell recognition, 
their reliable discovery and validation remains a major 
challenge. Most strategies are based on modelling which 
peptides bind to the MHC-I molecule. Most neoepitope 
studies identify thousands of somatic mutations and pre-
dict a much smaller number of MHC binders. However, 
given that fewer than 0.3% of mutations can be confirmed 
as neoantigens, the chances for successful personalised 
immunotherapy might appear to be limited. At the San 
Diego Center for Precision Immunotherapy, a novel plat-
form to identify neoantigens has been developed involv-
ing a combination of genomic sequencing, bioinformatic 
analysis, and functional testing of autologous PBMC 
or TILs (Fig.  2). This has minimal tissue and peripheral 
blood mononuclear cell requirements, detects both 
 CD8+ and  CD4+ T cell responses and can verify 20 to 
> 60% of selected mutations as neoantigens. The platform 
detects both driver and passenger mutations and can be 
used with low mutational burden tumours. Identifying a 
tumour-specific antigenic mutanome can be used as the 
basis for personalised immunotherapy and/or vaccina-
tion. To validate the neoantigen targets identified using 
this platform, we have developed a patient-derived xeno-
graft (PDX) system through which neoantigen-specific 
TIL are used in adoptive immunotherapy against autol-
ogous tumours. These studies have shown a direct rela-
tionship between the frequency of neoantigen-specific T 
cells in a given cellular product and its therapeutic effi-
cacy. These findings support the concept of truly person-
alized immunotherapy in which the specific neoantigens 
to be targeted are functionally validated on a per-patient 
basis.
Valuable biomarkers to direct therapy: are we any closer?
Multiple potential biomarkers to predict the response to 
immunotherapy are likely to be needed given the com-
plexity of the immune tumour microenvironment. How-
ever, the search for reliable biomarkers is limited by our 
incomplete understanding of how immunotherapies 
modify the already complex immune response to can-
cer. To be of clinical value, biomarkers need to be accu-
rate, reproducible, minimally invasive, dependent on 
clinical situation and able to direct optimal selection and 
sequencing of cost-effective therapy. Current candidates 
include PD-L1 expression,  CD8+ TILs, tumour muta-
tion load, neoantigen burden and gene expression pro-
file (GEP) (Table 1). PD-L1 tumour expression has been 
shown to correlate with response to anti-PD-1 antibod-
ies; however, the lack of expression does not preclude a 
response. Variability in assays, antibodies, and tumour 
cell types detected as well as determining optimal cut-off 
points represent challenges in using PD-L1 expression 
as a biomarker. Additionally, PD-L1 expression is heter-
ogenous and dynamic within an individual and can be 
induced by activated tumour-specific T cells; heteroge-
neity in PD-L1 expression is frequent within a sample as 
well as between the primary lesion and its metastases.
The presence of Tregs and expression of PD-L1 and 
IDO are associated with a  CD8+ cell infiltrate. T cell-
inflamed tumours showed high expression of IDO, 
PD-L1, and  FoxP3+ Tregs, suggesting that these inhibi-
tory pathways might serve as negative feedback mecha-
nisms that follow  CD8+ T cell infiltration [20].
Tumour mutation burden (TMB) has been shown to 
correlate with response to checkpoint blockade, sug-
gesting that the T cell response may be targeted to neo-
antigens that evolve as the mutation rate increases in 
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the tumour cell, rather than established antigens. TMB 
may be as predictive as neoantigen load for response 
to immunotherapy. In a study using whole-exome 
sequencing of non-small-cell lung cancer treated with 
pembrolizumab, higher mutation burden in tumours 
and clinical responses were correlated with molecu-
lar signature characteristics of tobacco carcinogen-
related mutagenesis, higher neoantigen burden, and 
DNA repair pathway mutations [21]. In 110 patients 
with melanoma, overall mutation load, neoantigen 
load and expression of immune microenvironment 
cytolytic markers were associated with clinical benefit, 
but no recurrent neoantigen peptide sequences pre-
dicted response to ipilimumab [22]. Mutational load, 
as determined by a next generation sequencing (NGS) 
platform available in the clinic may effectively stratify 
Fig. 2 Neoantigen discovery and functional validation
Table 1 Selected potential biomarkers for immunotherapy
Basis Challenges
PD-L1 IHC approach to measuring PD-L1 expression on tumour 
and immune cells
Variability in assays, antibodies and tumour microenviron-
ment
CD8+ T cells PD-1/PD-L1 expression on  CD8+ T cells predicts response to 
PD-1 agents
Optimal cut-off points, scoring metrics and agreement on 
magnitude of change needed for meaningful prediction 
of response
Tumour mutation load High mutation load resulting from various factors correlated 
with response to checkpoint inhibitors in exceptional 
responders
Availability of adequate tissue for sequencing; whole exome 
sequencing expensive and slow turnaround time vs. other 
clinical assays
Neoantigen burden Predict clinical benefit to ipilimumab and PD-1 blockade in 
melanoma and lung cancer
As above
Gene expression profiling IFN-induced signatures may predict response to checkpoint 
inhibitors
Sizable tissue collection needed to validate testing and 
training sets
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melanoma patients by likelihood of response to anti-
PD-1 therapy [23].
Genomic assessment of exceptional responders may 
reveal patient groups that are extremely sensitive to 
checkpoint inhibitor therapy and can help inform dif-
ferent mechanisms of response within the same disease 
cohort. For example, genomic profiling of a pretreat-
ment tumour sample from a patient with endometrial 
cancer who had an exceptional response to pembroli-
zumab identified a mutation in DNA polymerase epsi-
lon (POLE) that was associated with an ultramutator 
phenotype [24]. Analysis of TCGA revealed that the 
presence of POLE mutation is associated with high 
TMB and increased expression of several immune 
checkpoint genes, indicating that cancers with POLE 
mutations are potential candidates for checkpoint 
blockade therapy.
TMB does not, however, always correlate with treat-
ment response. This may be due to the poor dynamic 
range of the assays available or confounding by tumour 
purity, or because exome sequencing does not iden-
tify all types of mutations. The type of mutation may 
be as important as the number of mutations. In addi-
tion, immune activation may occur through processes 
that are independent of TMB, such as viral infection. 
Tumour samples from a patient with metastatic gas-
tric cancer who responded to the anti-PD-L1 anti-
body avelumab showed no evidence of high mutation 
burden or mismatch repair defect. However, the 
tumour was strongly positive for presence of Epstein-
Barr virus (EBV) encoded RNA and had evidence of 
immune infiltration, suggesting that EBV-positive low-
mutation burden gastric cancers have immune activa-
tion and may respond to immune checkpoint therapy. 
Thus, there may be multiple mechanisms of immune 
activation, which may be very similar with regard to 
immunological signature [25].
While mutational load reflects tumour antigenicity, 
GEP reflects activated T cells in the tumour micro-
environment. Analysis of GEPs using RNA from 
baseline tumour samples of pembrolizumab-treated 
patients resulted in the identification of an 18-gene 
immune-related signatures that was correlated with 
clinical benefit. This T cell-inflamed GEP contained 
IFN-γ-responsive genes related to antigen presenta-
tion, chemokine expression, cytotoxic activity and 
adaptive immune resistance and is currently being 
evaluated for potential diagnostic use in ongoing clini-
cal trials [26]. In data from the KEYNOTE-028 trial in 
patients with solid tumours, both mutational load and 
GEP score were independently predictive of clinical 
response [27].
How to establish precision medicine in metastatic 
melanoma
Multiplatform tissue processing can be used to help iden-
tify molecular characteristics of melanoma in order to 
help stratify patients for therapy. Whole exome sequenc-
ing (WES) can identify recurrent genomic aberrations, 
including somatic mutations in driver oncogenes (e.g. 
BRAF, NRAS, and KIT), tumour suppressor genes (e.g. 
CDKN2a, PTEN, and P53), inherited mutations in onco-
genes, and the presence of known and new candidate 
mutations that cause treatment resistance.
A melanoma-specific gene panel, known as MelAr-
ray, has been developed based on the WES at USZ and 
Yale University. This panel is composed of 195 mela-
noma mutant genes [single-nucleotide variants (SNVs), 
copy-number variants (CNVs) and gene fusions] and 
has a sequencing cost that is approximately 20% lower 
than WES. It provides deeper coverage of important loci, 
empirical CNV measurements, gene fusions, non-coding 
variants, HLA type and T-cell receptor (TCR) sequenc-
ing. CNVs in the tumour are reported with a reference 
to the affected gene, deletion or amplification. Onco-
genicity and mutation effects of CNVs and SNVs are 
reported in the oncogenic gene table, supported by litera-
ture references as evidence for the function of the onco-
genic mutation or copy number alteration. Actionable 
genes are reported by matching oncogenic genes to the 
OncoKB database. OncoKB is an expert-guided preci-
sion oncology database that annotates the biological and 
oncogenic effect and the prognostic and predictive sig-
nificance of somatic molecular alterations with the aim of 
supporting evidence-based treatment decision-making. 
To date, over 3000 unique mutations, fusions, and copy 
number alterations in 418 cancer-associated genes have 
been annotated. The oncogenic variant is listed with can-
cer type and corresponding treatment together with level 
of evidence. In an analysis of 83 melanoma samples, 70 
had a potential drug for their specific oncogenic variant.
High-dimensional single-cell mass cytometry (CyTOF) 
can be used to characterise immune cell subsets in the 
peripheral blood of patients. Antibodies are labelled with 
metal isotopes rather than fluorochromes which avoids 
spectral overlap or autofluorescence problems. Simulta-
neous analysis of a large number of markers (> 50) is pos-
sible and barcoding allows analysis of multiple samples 
at the same time. Algorithm-guided analysis allows the 
clustering of cell subtypes. Assessment of changes in of 
responders versus non-responders before and after treat-
ment allows for identification of potential biomarkers of 
response or the mechanism of the drug action. A strong 
predictor of response to anti-PD-1 treatment was the 
frequency of  CD14+CD16−HLA−DRhi monocytes [28]. 
Responders also had a lower frequency of circulating 
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 CD4+ T effector cells and  CD8+ naïve T cells. In addi-
tion, numbers of multifunctional  CD8+ cells expanded 
and CTLA-4 and Granzyme B expression levels were 
higher in responders. Several myeloid markers were 
upregulated in responders compared with non-respond-
ers. As such the frequency of monocytes in peripheral 
blood mononuclear cells may help in clinical decision-
making regarding anti-PD-1 therapy.
Combination strategy session
How much better are anti‑CTLA‑4 plus anti‑PD‑1 
combinations than anti‑PD‑1 alone
In the CheckMate-067 study of patients with advanced 
melanoma, combination therapy with nivolumab plus 
ipilimumab was associated with significantly longer OS 
than with ipilimumab alone [29]. Three-year OS was 58% 
with combined nivolumab plus ipilimumab, 52% with 
nivolumab alone and 34% with ipilimumab alone. On the 
basis of these findings, treatment with either combined 
anti-PD-1/anti-CTLA-4 therapy or PD-1 monotherapy 
appear to be reasonable options given the absence of a 
significant OS difference. However, it is possible that cer-
tain patient subgroups may derive more benefit from the 
combination than single agent anti-PD-1. In subgroup 
analysis, BRAF status, PD-L1 expression < 1% and region 
(US vs. EU) were the only factors that may be associated 
with OS benefit to the combination compared to single 
agent anti-PD-1, with region (US vs. EU) being the only 
significant factor in multivariate analysis [30]. The rea-
sons for this are unclear as treatment exposure, manage-
ment of adverse events, and use of subsequent therapies 
did not differ substantially between the two regions.
Further evidence on who to treat with combination 
therapy vs. anti-PD-1 alone is needed. Blood-based bio-
markers [high LDH, low relative lymphocytes, low rela-
tive eosinophils, and presence of visceral (non-lung) 
metastases] have been associated with poor outcomes 
among patients treated with pembrolizumab [15]. Some 
of these factors have also been found to be associated 
with worse survival with nivolumab plus ipilimumab 
as well. An examination of these factors in the Check-
mate 067 study is needed to see if they help distinguish 
which patients may benefit most from combination 
immunotherapy.
Patients with melanoma brain metastases are another 
group who might be considered for combination immu-
notherapy. In the Anti-PD-1 Brain Collaboration (ABC) 
study, intercranial response rate was higher in patients 
treated with combined nivolumab plus ipilimumab versus 
nivolumab alone [31]. Intercranial PFS was also improved 
with combination therapy (6-month median PFS rate of 
46% vs. 28% with monotherapy).
Choice of combined anti-PD-1/anti-CTLA-4 therapy 
or PD-1 monotherapy may be influenced by patient fac-
tors, such as their resilience to increased early toxici-
ties as well as their reliability in reporting any such side 
effects. Combination therapy may also be preferable for 
patients that need treatment with a higher response rate, 
given the lack of a clearly proven survival benefit. Newer 
dosing regimens of combination anti-CTLA-4 and anti-
PD-1 are being tested to see if the high degree of efficacy 
of the current nivolumab + ipilimumab combination can 
be maintained with more favourable tolerability.
Combining oncolytic therapy with checkpoint inhibitors
An immune-active tumour microenvironment and type I 
IFN transcriptional signature are associated with clinical 
benefit from immunotherapy suggesting that strategies 
targeting the type I IFN pathway could sensitize tumours 
to immune checkpoint blockade. Intralesional tumour 
therapy with oncolytic viruses results in type I IFN pro-
duction and immunogenic cell death. Talimogene laher-
parepvec (T-VEC) is an oncolytic virus therapy based 
on a modified herpes simplex virus type-1 (HSV-1) that 
is designed to selectively replicate in tumours. T-VEC 
administration produces granulocyte–macrophage col-
ony-stimulating factor (GM-CSF) and enhances local 
and systemic anti-tumour immune responses, caus-
ing regression in injected lesions and inducing immune 
responses that mediate regression at uninjected sites. In 
a phase III clinical trial, T-VEC was well tolerated and 
resulted in a higher durable response rate and longer 
median OS than subcutaneous GM-CSF administration 
[32]. In an open-label, multicentre trial, T-VEC in com-
bination with ipilimumab, had a tolerable safety profile, 
ORR of 50%, 18-month PFS of 50% and 18-month OS 
of 67% [33]. Thus, the combination appeared to have 
improved efficacy compared with either T-VEC or ipili-
mumab monotherapy. Total frequency and activated 
CD8 T cells increase after T-VEC and after T-VEC plus 
ipilimumab. In the first randomised trial to evaluate addi-
tion of an oncolytic virus to a checkpoint inhibitor, ORR 
was significantly higher with T-VEC plus ipilimumab ver-
sus ipilimumab alone (39% vs. 18%; odds ratio 2.9; 95% 
CI 1.5–5.5; p = 0.002) [34]. With a median follow-up of 
14.7 months, median PFS was 8.2 months (95% CI 4.2–
21.5) in the combination and 6.4 (95% CI 3.2–16.5) with 
ipilimumab alone. The combination was tolerable with no 
unexpected safety findings with comparable gastrointes-
tinal toxicity to the combination arm.
Another replication-competent oncolytic virus 
derived from HSV-1 is HF10, a spontaneously occur-
ring HSV-1 mutant. A phase II trial of HF10 plus ipili-
mumab in patients with unresectable or metastatic 
melanoma demonstrated a favourable risk–benefit profile 
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and encouraging antitumour activity, with best ORR at 
24 weeks of 41% [35]. Treatment was well tolerated with 
no dose-limiting toxicities; most HF10-related adverse 
events were ≤ grade 2 and similar to those with HF10 
monotherapy.
The combination of oncolytic virus and anti-PD-1 ther-
apy may be an especially attractive option for patients 
who progress after first-line treatment with PD-1 agents 
and have injectable lesions, although this group of 
patients has not been extensively studied. In addition to 
T-VEC and HF10, several other oncolytic viruses are in 
development (e.g. Newcastle disease virus, Coxsackie 
virus) as well as other locally administered treatments 
and selection of the most appropriate therapy for indi-
vidual patients becomes an increasing issue as treatment 
options expand. As such, biomarkers for selection are an 
important consideration.
Combining electrochemotherapy and checkpoint 
inhibitors
Electrochemotherapy (ECT) is a tumour ablation modal-
ity that involves the local application of short dura-
tion high-voltage pulses in order to produce a transient 
increase in cell membrane permeability to cytotoxic 
chemotherapeutic drugs, such as bleomycin or cisplatin. 
ECT is reliable, effective and safe and can be used to treat 
(1) early cutaneous relapses after previous surgical treat-
ment, (2) complete or partial progression after previous 
ECT treatment, (3) as palliative treatment of haemo-
static or painful lesions, and (4) as neoadjuvant therapy 
for extensive lesions to reduce surgical approach. Several 
studies of ECT in patients with advanced melanoma have 
been reported and suggest good response rates and dura-
ble benefits. In a study of 60 patients with relapsed and 
refractory cutaneous melanoma metastases or in-transit 
disease who underwent 100 courses of ECT with intrave-
nous injection of bleomycin, long-term durable benefits 
were achieved without a negative impact on quality of life 
[36]. ECT is inexpensive, simple to apply, well tolerated 
and appears to be an effective procedure for the local 
treatment of malignant tumour nodules, and objective 
responses under certain circumstances. However, there 
is no evidence that ECT alters the natural disease course 
and it should therefore be considered a palliative treat-
ment [37].
ECT may also be used as a part of a more integrated 
approach with other treatment modalities, such as 
immunotherapy. An abscopal effect has been reported 
in patients treated with ipilimumab and radiotherapy 
(RT), in which radiation of a tumour causes regression 
of untreated distant skin lesions [38]. Although not well 
understood, it has been proposed that this is an immune-
mediated phenomenon, suggesting that immunotherapy 
and RT could have potentially synergistic effects. Simi-
larly, it is possible that immune checkpoint blockade 
might also be able to improve the effects of ECT. In a 
retrospective analysis of 15 patients with previously 
treated metastatic melanoma who received ipilimumab 
with ECT, a local ORR was observed in 67% of patients 
[39]. In a comparison of ipilimumab alone versus ipili-
mumab plus local peripheral treatments (i.e. radiother-
apy or electrochemotherapy) in 127 melanoma patients, 
the addition of local treatment significantly prolonged 
OS without increased toxicities [40]. ECT in combina-
tion with immunotherapy appears to be feasible, toler-
able and associated with potent anti-tumour activity 
and high response rates. However, the optimal timing of 
ECT in combination with immunotherapy needs further 
investigation.
Adjuvant therapy of melanoma
Until recently, IFN-α was the only approved drug for 
the adjuvant therapy of patients with melanoma at high-
risk of recurrence after surgical resection. However, 
the use of IFN-α remains controversial, with ongoing 
debate over the optimal dose and regimen. A 1-year regi-
men comprising of a high-dose IV induction phase fol-
lowed by a subcutaneous maintenance phase has been 
accepted as standard in the US and elsewhere. However, 
the 1-year treatment duration, associated toxicity, and 
uncertainty over survival benefit has limited its utilisa-
tion. In the E1697 trial, 4 weeks of IV induction did not 
improve 5-year OS compared with observation alone 
and was associated with worse quality of life in patients 
with intermediate-risk melanoma [41]. Another option, 
pegylated-IFN, allows a lower once weekly dose and sig-
nificantly improved recurrence-free survival (RFS) versus 
observation in the EORTC 18991 trial, although there 
was no significant difference in OS [42]. However, almost 
one-third of patients discontinued therapy due to toxic 
adverse effects. The future role of IFN as adjuvant treat-
ment is unclear, although it may have a role in patients 
with ulcerated tumours [43].
High-dose ipilimumab was approved for adjuvant 
treatment of melanoma in the US in 2015. This was 
largely based on a study of 951 patients who had under-
gone complete resection of stage III cutaneous mela-
noma in which ipilimumab 10  mg/kg resulted in a 
significantly higher 5-year OS rate than placebo, with a 
28% risk reduction for death (HR, 0.72; 95.1% confidence 
interval [CI] 0.58–0.88; p = 0.001) [44]. However, drug-
related toxicity was a major concern with 48% of patients 
receiving ipilimumab discontinuing treatment. Given 
the dose-dependency of ipilimumab toxicity, the efficacy 
and safety of lower dose ipilimumab 3 mg/kg as adjuvant 
therapy is currently been investigated in the E1609 study. 
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In preliminary results, ipilimumab 3 mg/kg showed simi-
lar RFS as ipilimumab 10  mg/kg with significantly less 
toxicity [45].
Several other trials of adjuvant checkpoint inhibitor 
or targeted therapy are ongoing (Table 2). In the Check-
Mate-238 trial, ipilimumab 10 mg/kg was compared with 
nivolumab 3 mg/kg in 906 patients after complete resec-
tion of stage IIIB-IV melanoma [46]. RFS at 1  year was 
70.5% (95% CI 66.1–74.5) in the nivolumab group com-
pared with 60.8% (95% CI 56.0–65.2) in the ipilimumab 
group (HR for disease recurrence or death, 0.65; 97.56% 
CI 0.51–0.83; p < 0.001). The RFS benefit seen with 
nivolumab was observed in several subgroups, including 
those categorised by PD-L1 expression, BRAF status or 
disease stage. Nivolumab was also better tolerated, with 
fewer treatment-related grade 3–4 adverse events and 
discontinuations compared with ipilimumab. Based on 
these results, nivolumab has the potential to be a new 
standard of care for patients with resected stage IIIB-IV 
melanoma, regardless of BRAF status. Nivolumab was 
approved by FDA in the treatment of adjuvant melanoma 
on December 2017.
Adjuvant use of targeted agents has also been reported. 
In the BRIM-8 trial, 1  year of adjuvant monotherapy 
with the BRAF inhibitor vemurafenib provided a sig-
nificant improvement in disease-free survival (DFS) 
(46% risk reduction, p = 0.0010) compared with pla-
cebo in 314 patients with resected stage IIC, IIIA or IIIB 
BRAF-mutated melanoma [47]. However, in a cohort of 
184 patients with stage IIIC BRAF-mutated melanoma, 
the increase in median DFS with adjuvant vemurafenib 
was not significant (23.1 vs 15.4  months; HR 0.80, 95% 
CI 0.54–1.18; p = 0.2598). Treatment was generally 
well tolerated, with no increase in secondary skin can-
cers [cutaneous squamous cell carcinoma (SCC) and 
keratoacanthoma (KA)] known to be associated with 
vemurafenib.
BRAF inhibition has also been assessed in combination 
with MEK inhibition. In the Combi-AD trial of adjuvant 
dabrafenib plus trametinib in stage III BRAF-mutated 
melanoma, estimated 3-year RFS was 58% with combina-
tion therapy (n = 438) versus 39% with placebo (n = 432) 
(HR for relapse or death, 0.47; 95% CI 0.39–0.58; 
p < 0.001) [48]. Three-year OS was 86% with the combi-
nation compared with 77% in the placebo group (HR for 
death, 0.57; 95% CI 0.42–0.79; p = 0.0006). However, 41% 
of combination-treated patients had grade 3–4 adverse 
events and 26% discontinued treatment because of toxic 
effects.
In summary, use of IFN as adjuvant therapy can be 
considered to be in its ‘retirement’ phase. High-dose 
ipilimumab is approved in the US but anti-PD-1 agents 
appear to be more effective and better tolerated, while 
combined BRAF and MEK inhibition may have a role 
in BRAF-mutated melanoma. The debate over whether 
to choose immunotherapy or targeted therapy has now 
extended to the adjuvant setting.
Conclusions
Advances in the treatment of advanced melanoma have 
significantly improved the long-term prognosis for 
patients in recent years. While treatment was previ-
ously generally considered as being of palliative intent, 
the development of novel immunotherapies and targeted 
agents has completely altered the therapeutic landscape. 
Treatment with these agents has resulted in survival out-
comes significantly improved as compared to what was 
previously achieved with other treatment modalities such 
as chemotherapy. The focus is now on achieving greater 
treatment efficacy through the use of various combina-
tion approaches, including combinations of different 
immunotherapies as well as with non-immunothera-
peutic options, in particular the new targeted therapies. 
Doublet and even triplet combinations involving these 
new agents will likely become new gold standards of care. 
However, more research to identify the optimal combi-
nation and sequencing of treatments is needed. Moreo-
ver, in order to maximise the benefits of these various 
new treatment options, selection of the most appropri-
ate patients for therapy is essential. Various candidate 
Table 2 Ongoing adjuvant trials
Study No. of patients TNM stage Therapy Primary endpoint
US Intergroup E1609 1600 III (IIIB–c), IV (M1a, M1b) Ipilimumab 3 mg/kg or 10 g/kg vs HD-IFN RFS, OS
COMBI-AD 852 III (BRAF V600E/K) Dabrafenib + trametinib vs. placebo RFS
BRIM-8 725 IIC, III (BRAF V600; Cobas) Vemurafenib vs. placebo DFS
EORTC-1325/KEYNOTE-054 900 IIA (> 1 mm met), IIIb–C Pembrolizumab vs. placebo RFS, RFS in PDL1+
CheckMate-238 800 IIIB–C, IV Nivolumab vs. ipilimumab 10 g/kg RFS
US Intergroup S1404 1240 IIIA (N2), IIIB–C, M Pembrolizumab vs. HD-IFN or ipilimumab 10 mg/kg RFS, OS
C heckMate-915 1125 IIIB–D, IV Ipilimumab + nivolumab vs ipilimumab or nivolumab RFS
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biomarkers [e.g. PD-L1 expression,  CD8+ TILs, tumour 
mutational burden (TMB), neoantigen burden, tran-
scriptomic profiling, blood-based biomarkers] are being 
investigated to help identify patients who most likely will 
benefit and to assist with increasingly complex treat-
ment decision-making. The development of biomarkers 
remains a focus of the personalized medicine approaches 
to guide the use of novel therapeutic strategies to the 
most appropriate patients.
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